Study of TP-04 in Participants With Papulopustular Rosacea

NCT05838170 PHASE2 COMPLETED

This study is being done to evaluate the safety, tolerability, and efficacy of the study drug, TP-04, in participants with papulopustular rosacea (PPR).

Details

Lead sponsor	Tarsus Pharmaceuticals, Inc.
Phase	PHASE2
Status	COMPLETED
Enrolment	37
Start date	Wed Mar 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Nov 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Papulopustular Rosacea

Interventions

• Lotilaner Gel, 2.0%
• Vehicle control gel

Countries

Canada